Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Lenvatinib synthesis cyclopropyl isocyanate patent?

See the DrugPatentWatch profile for Lenvatinib

I don’t have enough information from the prompt to identify the specific “cyclopropyl isocyanate” lenvatinib synthesis patent you mean (for example, the patent number, assignee, or publication country), so I can’t reliably state claims, filing/priority dates, or whether it covers a specific intermediate.

What patent is it (and how to find the right one)?

Search the patent databases using combinations of:
- “lenvatinib” AND “cyclopropyl isocyanate”
- “cyclopropyl isocyanate” AND “lenvatinib synthesis”
- “isocyanate” AND “cyclopropyl” AND “lenvatinib”
Then filter for patent documents (not articles) and check the assignee/company and the “intermediates” sections or examples where isocyanates are prepared/used.

If you share any one of the following, I can narrow it down precisely and summarize what the patent covers:
- patent publication number (e.g., WO/US/EP + number)
- assignee/company name
- a link or screenshot of the patent text where “cyclopropyl isocyanate” appears
- the specific intermediate name used in the example (sometimes the document uses a code name rather than the plain chemical name)

Does the patent cover making the cyclopropyl isocyanate itself or using it in lenvatinib?

Patents on syntheses often split into different types of coverage:
- Methods for preparing an intermediate (process claims)
- Intermediates themselves (compound claims)
- Methods for producing lenvatinib using that intermediate (use in final/advanced-step claims)

The “cyclopropyl isocyanate” phrase might appear as:
- a reagent purchased as starting material, or
- an intermediate prepared in a step described in the examples, or
- a key step in converting an amine to the corresponding urea/carbamoyl linkage in the lenvatinib route.

Which of these it is determines what claim scope you’re actually asking about.

How long would such a patent last (basic timing)?

If you find the exact publication, the typical expiration logic depends on the jurisdiction and whether it’s a patent term with possible extensions:
- Standard patent term is often 20 years from the earliest priority date, subject to adjustments/extension rules.
- Longer effective life can happen via supplementary protection mechanisms in some regions (e.g., Europe), but only if eligibility is met.

What to check in the claims (to see if it really covers the synthesis step)?

Once you identify the correct document, check:
- Whether claims mention “cyclopropyl isocyanate” by name, or a generic definition (e.g., “cycloalkyl isocyanate”)
- Whether claims describe the isocyanate preparation step (carbonylation/phosgenation routes, etc.) or only its use downstream
- Whether it’s limited to particular conditions, catalysts, temperatures, or solvents (which can narrow infringement risk)
- Whether there are multiple examples showing fallback routes

If you meant a competitor’s freedom-to-operate angle

People sometimes search this way because a synthesis patent can affect:
- contract manufacturing of lenvatinib intermediates,
- sourcing the intermediate (supplier patent constraints), or
- process changes that avoid the specific intermediate/reagent step.

To answer that angle, you’d need the exact patent(s) and the relevant geography.

Next step

Send the patent publication number (or paste the claim text/snippet where “cyclopropyl isocyanate” appears). Then I can:
- identify the patent family,
- summarize what it claims about cyclopropyl isocyanate in the lenvatinib synthesis,
- and explain how/when it would typically expire based on its priority dates.

Sources

No sources were used because no specific patent document (number/link) was provided.



Other Questions About Lenvatinib :

is generic lenvatinib available ? Generic lenvatinib? Lenvatinib mark cuban? Lenvatinib fda approval history? Bc cancer lenvatinib? Lenvatinib price in malaysia? Lenvatinib patent expiry?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: High

Summary

The AI response contains a direct contradiction to the FDA label regarding contraindications.


Category Scores

Contraindications
0
Poor

Accurate Statements

The FDA label states there are no contraindications for LENVIMA.
Section 4: "CONTRAINDICATIONS None."

Unsupported Statements


Contradictions

High

AI Statement
LENVIMA is contraindicated.

Label Reference
Section 4: "CONTRAINDICATIONS None."


Important Omissions


Safety Assessment

Potential Patient Risk: High
A statement that LENVIMA is contraindicated conflicts with the label and could lead to improper clinical exclusion or misunderstanding of labeled safety constraints.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Not Aligned

Primary Issue
Direct contradiction: the response states LENVIMA is contraindicated, while the label states there are no contraindications.

Suggested Improvement
Replace the contradictory claim with the label-consistent statement that LENVIMA has no contraindications (Section 4).

Drug Brand Mention Assessment

Branding Score
35
Visibility
26
Mentioned
Ranking
#2
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • The response cannot identify the specific lenvatinib synthesis patent meant.
  • It suggests searching using combinations including “lenvatinib” and “cyclopropyl isocyanate”.
  • It explains that patents may cover making an intermediate or using it in lenvatinib.
Differentiators
  • Emphasizes that coverage depends on whether the phrase appears as a reagent or prepared intermediate.
  • Recommends filtering for patent documents and checking assignee and “intermediates” sections/examples.

Pricing Perception: Not Mentioned